Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT - Université de Lorraine Access content directly
Journal Articles Bone Marrow Transplantation Year : 2021

Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

Mohamad Mohty
Stella Santarone
  • Function : Author
Nicolaus Kroger
Didier Blaise
Yves Chalandon
Pietro Pioltelli
  • Function : Author
Carlos Solano
  • Function : Author
Juan Carlos Hernandez-Boluda
Donal Mclornan
No file

Dates and versions

hal-03628347 , version 1 (01-04-2022)

Identifiers

Cite

Giorgia Battipaglia, Katya Mauff, Lotus Wendel, Emanuele Angelucci, Mohamad Mohty, et al.. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56 (7), pp.1593-1602. ⟨10.1038/s41409-021-01222-z⟩. ⟨hal-03628347⟩
44 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More